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Abstract
Objective
One of the greatest challenges in clinical trial design is dealing with the subjectivity and vari-
ability introduced by human raters when measuring clinical end-points. We hypothesized
that robotic measures that capture the kinematics of human movements collected longitudi-
nally in patients after stroke would bear a significant relationship to the ordinal clinical scales
and potentially lead to the development of more sensitive motor biomarkers that could
improve the efficiency and cost of clinical trials.
Materials and methods
We used clinical scales and a robotic assay to measure arm movement in 208 patients 7,
14, 21, 30 and 90 days after acute ischemic stroke at two separate clinical sites. The robots
are low impedance and low friction interactive devices that precisely measure speed, posi-
tion and force, so that even a hemiparetic patient can generate a complete measurement
profile. These profiles were used to develop predictive models of the clinical assessments
employing a combination of artificial ant colonies and neural network ensembles.
Results
The resulting models replicated commonly used clinical scales to a cross-validated R2 of
0.73, 0.75, 0.63 and 0.60 for the Fugl-Meyer, Motor Power, NIH stroke and modified Rankin
scales, respectively. Moreover, when suitably scaled and combined, the robotic measures
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demonstrated a significant increase in effect size from day 7 to 90 over historical data (1.47
versus 0.67).
Discussion and conclusion
These results suggest that it is possible to derive surrogate biomarkers that can significantly
reduce the sample size required to power future stroke clinical trials.
Introduction
Stroke is the leading cause of permanent disability in the United States [1]. With the demo-
graphic profiles of most developed countries shifting towards older individuals, disability due
to stroke is projected to increase significantly in future years. As such, there is great interest in
finding pharmacological agents to promote neuro-protection and neuro-recovery as well as in
reducing the cost of clinical trials [2]. We chose to investigate the use of robotic systems
because of their growing adoption in stroke wards to deliver therapy. However, many robotic
devices, such as the InMotion Arm [3], afford not only the possibility to promote faster and
better rehabilitation, but also the potential to track an individual’s progress [4–6].
An important potential advantage of robotic devices over “traditional” clinical instruments
is that the measurement variability due to the skills and expertise of the rater can be removed
from the assessment process. It has been shown repeatedly that standard clinical scales, such as
the Fugl-Meyer assessment (FM) [7], show a high degree of variability among different raters
[8], ultimately leading to larger sample sizes being required to demonstrate the value of a par-
ticular intervention [9]. Thus, the ability to remove inter- and intra-rater variability as well as
conduct the assessments more efficiently would enable faster and less costly clinical trials [10].
However, the correlation between robotic assays and established clinical scales—such as the
NIH stroke scale (NIH) [11], the modified Rankin scale (MR) [12, 13], or the FM—remains an
open question. Although these scales have some important shortcomings, their use has been
widespread and there are a large number of legacy trials that have recorded one or all of them.
To properly leverage the information captured in these historical trials, we need a method for
mapping the results from the robotic measurements to these conventional clinical assessments.
Furthermore, because robotic assays have not been approved for use as clinical endpoints by
the FDA, it must, at a minimum, be demonstrated that they capture information similar to
that of the currently approved instruments. Prior work has shown that robotic measures corre-
lated well with the FM [14]. However, those were derived from chronic stroke during a period
when most pharmacological interventions ceased. Additionally, that work employed linear
combinations of different robotic measurements [14–18]. Although the correlations were
good, they suggested the potential to construct a much improved and more accurate predictor
using non-linear techniques specifically neural networks. The central goal of this work was to
demonstrate that we can use the same metrics to reconstruct existing clinical scales as well as
derive composites that are more sensitive the change over time as patients recover from stroke.
Given the limitations of existing stroke scales [19, 20], we believe that with the advent of new
digital biomarkers, we can do better.
Here, we provide methods and modeling details of a longitudinal study involving 208
patients who had suffered severe to moderate acute ischemic stroke and were assessed with
four commonly used clinical instruments [21]–NIH stroke scale (NIH), Fugl-Meyer assess-
ment (FM), Motor Power (MP) [22, 23] and modified Rankin scale (MR)–as well as with a
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robotic assay to measure arm movement 7, 14, 21, 30, and 90 days after the stroke onset. We
hypothesized that by utilizing nonlinear models obtained through a rigorous feature selection
algorithm, we could improve our prediction of the standard clinical scales. We hypothesized
that the different clinical scales are in part functions of gross motor movements that are non-
linear combinations of individual movement components that are being recorded by the
robotic apparatus [24]. Thus, for any effective reconstruction of these clinical scales, a nonlin-
ear modeling strategy must be adopted. Here, we utilize artificial ant colonies and neural net-
work ensembles to reconstruct the clinical scores with a high degree of accuracy that is
comparable to the level of agreement among different expert raters (cross-validated R2 of 0.75,
0.73, 0.63 and 0.60 for MP, FM, NIH and MR, respectively). Further, we demonstrate that the
robotic measurements, due to the use of systematic and objective measurements, are able to
reduce variability even in the case of a single highly trained rater.
Methods
Study population
In this study, 208 patients who had suffered acute stroke (defined as patients with a baseline
NIH of 7–20 recorded at day 7 days since stroke onset) were enrolled and were given a battery
of standard clinical assessments including the NIH, FM, MR and MP [25] measured only on
the affected side as per standard practice. Of these four, two clinical scales are of prime interest
to us, the NIH and the FM. These patients were evaluated on days 7, 14, 21, 30, and 90 after the
initial stroke. The subjects were distributed between two sites: the Burke Rehabilitation Center
in New York (145 patients) and the Western Infirmary in Glasgow, Scotland (63 patients). To
minimize inter-rater variability, the patients were assessed by a single highly trained clinician
at Burke and two highly trained clinicians at Glasgow. In addition to the clinical scales, each of
the patients was also evaluated with the InMotion robot [3], a commercial version of the MIT-
Manus robot, to obtain a battery of robot-measured kinematic and kinetic (RMK) variables.
For the RMK battery, each patient was evaluated twice, once on the side of the body affected
by the stroke and once on the unaffected side, in order to explore any potential relationships
between them. The RMK measurements for each patient took approximately 60 minutes to
complete (40 minutes for the affected side, which for severe patients required assistance with
each move, and 20 minutes on the unaffected side), whereas the standard clinical assessments
took as long as 90 minutes.
Robot measured kinematics and kinetics
The RMK battery consists of several metrics derived from various directed unassisted reaching
tasks, circle drawing, resistance to external forces, and shoulder strength measurement. These
metrics are listed in Table 1. The directed reaching tasks are broken down into 8 macro-met-
rics and 6 micro-metrics [26]. The macro-metrics involve metrics such as the deviation from a
straight line when reaching for different targets (“Deviation”), aim to the targets (“Aim”),
movement average (Mean Speed), peak speed (“Peak Speed”) and duration (“Duration”) of
movement, and three different smoothness metrics which involve the movement mean speed
divided by the peak speed (“Smooth M/P”), a jerk metric which corresponds to the magnitude
of jerk divided by the peak speed (“Smooth J1”–best for discrete movements), and a jerk metric
which corresponds to the root mean square of the jerk normalized by the duration of the
movement (“Smooth J2”–best for rhythmic movements). It has been demonstrated that
unconstrained discrete and rhythmic reaching movements of healthy subjects minimize jerk
[27, 28].
PLOS ONE Accurate prediction of clinical stroke scales from robotic measurement
PLOS ONE | https://doi.org/10.1371/journal.pone.0245874 January 29, 2021 3 / 23
The same reaching tasks are broken down further into sub-movements as described by
Novak et al [29]. There are then decomposed into various micro-metrics such as the number
of sub-movements (“Numb Subm”), duration of sub-movement (“Dur Subm”), degree of sub-
movement overlap (“Overlap Subm”), sub-movement peak (“Max Subm”), inter-peak interval
(“Dist Subm”), and sub-movement skewness (“Sigma Subm”). The circle drawing task yields a
metric relating the ability to coordinate the shoulder and elbow independently, characterized
by the ratio of the major to the minor axis of an ellipse fitted to the attempted circle drawing
(“Ellipse”). Finally, the movement against resistance evaluates the ability of the subject to move
the actuator against a particular level of robotic resistance (“Rnd Dyn Mean Dist Measure”) as
well as the ability to keep the robotic actuator still while the robot attempts to move the actua-
tor (“Plbck Mean”). This leads to a total of 17 individual metrics being tracked by the RMK
system. Given that the RMK metrics are evaluated for both the affected and unaffected sides,
this leads to a total of 34 robotic variables that are captured for each patient. This set is com-
pleted by one final kinetic variable called Mean Z (“Mean Z”), which measures the mean
shoulder strength (Z force) for flexion, extension, abduction, and adduction. Because of the
sensor’s range and the fact that most patients would hit the instrument ceiling on their unaf-
fected arm, Mean Z was measured only on the affected side.
Since the RMK endpoints used a variety of units and the assessments fell across widely
divergent ranges, each endpoint was linearly normalized from 0 to 1 using the formula:
x0ðr; p; tÞ ¼
�













where x(r, p, t) represents the measurement of the r-th RMK variable for the p-th patient at the
t-th time point, and min(.) and max(.) run across all patients and time points for that variable.
Table 1. Overall description of the different RMK metrics.
Measurement Metrics Abbreviation Additional Description
Primary Motion Aim Aim
Deviation of Path Deviation Maximum distance between straight-line path vs. patient motion
Average Speed Mean Speed
Peak Speed Peak Speed
Movement Duration Duration Time To Reach Target
Jerk Metric Smooth M/P Mean Speed/Peak Speed
Jerk Metric 1 Smooth J1 Jerk Metric Normalized by Peak Speed
Jerk Metric 2 Smooth J2 Jerk Metric Normalized by Duration
Circle Drawing Ellipse Difference between major and minor axis for a drawn circle
Sub-Movements Number of Sub-movements Numb Subm Number of sub-movements
Duration of Sub-movements Dur Subm Average Width of sub-movement velocity profile
Sub Movement Overlap Overlap Subm Degree of Overlap between sub-movements
Sub Movement Peak Max Subm Maximum Height of the sub-movements
Sub Movement Skewness Sigma Subm Statistical Skewness of sub-movements
Sub Movement Intervals Dist Subm Interpeak Interval of sub-movements
Power Static Resistance Plbck Resistance against force generated by robot
Dynamic Resistance Rnd Dyn Average distance moved vs. Set Resistance Level
Shoulder Strength Mean Z Resistance against force generated by robot in the vertical direction
https://doi.org/10.1371/journal.pone.0245874.t001
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Feature selection
As mentioned earlier, our working assumption is that the different clinical scales are functions
of gross motor movements which are implicitly captured by the various RMK variables
recorded by the robotic apparatus. To test this hypothesis, we used a machine learning
approach aimed at predicting the clinical scores of a given patient on a given day from the
RMK variables measured for that patient on that same day. Models were derived indepen-
dently for each clinical scale, as different scales may capture different aspects of motor move-
ment and thus require a different subset of RMK variables for effective reconstruction. Each
patient contributed at most 6 records to the training set, one for each day for which an RMK
and clinical assessment were made (days 7, 14, 21, 30 and 90 plus some patients were also eval-
uated at day 3). If either the clinical score or any of the RMK variables were missing, that
record was excluded from the data set. (The day on which the measurement was made was not
included as an independent variable.).
To build robust models, one must guard against over-fitting. Over-fitting arises when the
number of features or adjustable parameters in the model substantially exceeds the number of
training samples. The presence of excessive features can cause the learning algorithm to focus
attention on the idiosyncrasies of the individual samples and lose sight of the broad picture
that is essential for generalization beyond the training set. A common solution to this problem
is to employ a feature selection algorithm to identify a subset of relevant features and use only
them to construct the actual model [30]. An exhaustive search is usually impractical since it
involves 2N possible combinations where N is the total number of available features, or N!
ðN  KÞ!K!
combinations if the desired number of features K is prescribed. Several feature selection algo-
rithms have been devised ranging from simple greedy approaches, such as forward selection or
backward elimination, to more elaborate methodologies, such as simulated annealing, evolu-
tionary programming and genetic algorithms [31].
In the present work, we use a feature selection algorithm based on artificial ant colonies
that was originally designed to model the biological properties of chemical compounds [32,
33]. Algorithms based on artificial ant systems are inspired by the fact that real ants, using
deposits of pheromone as a communication agent, are able to find the shortest path between a
food source and their nest [34]. A moving ant marks its path by depositing pheromone on the
ground. Although each individual ant moves at random, it can detect pheromone trails and
follow one of them with a probability proportional to the amount of pheromone on the trail.
By adding its own pheromone deposits, the ant reinforces the trail and makes it more attractive
to the other ants. While all paths are initially equally probable, the shorter ones encounter
more ants making round trips to the food source per time unit and, therefore, receive more
pheromone. Thus, short paths become increasingly more attractive to the ants, and eventually
all ants follow the shortest trail.
For feature selection, we consider the selection of a variable as a step of the real ant’s path;
therefore, the whole path represents a choice of a particular subset of K variables out of all N
variables. Each variable k, k = 1. . .N, is assigned a weight wk that is used to calculate the proba-
bility pk with which the variable is randomly selected by an ant. Initially, the weights (and prob-
abilities) for all variables are equal, (wk = w0 for all k). After the first ant has selected a subset of
K variables, a model is built using those variables and the quality of that model is used to com-
pute the “length” L of the ant’s path (the better the quality of the model, the shorter the path).
The path length L is derived from the model’s training R2 using Eq 2:
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which increases 10-fold as R2 decreases by 0.2 up to a R2 value of ~0.2, and thus provides ade-
quate differentiation between feature subsets, while more severely penalizing solutions with R2
values lower than 0.2 (Fig 1). This formula was derived empirically and has worked well in
other similar contexts [30, 31].
After L has been calculated, the weights corresponding to the selected variables are updated
according to the following rule:




where t is the ant’s number, ρ is the evaporation coefficient that simulates the evaporation of
the pheromone from the real ants’ paths, and Δw is a constant factor. The next ant calculates





The process is repeated for the specified number of ants, and the best selection found is
reported. Variables that contribute to good solutions (small L, high R2) end up with larger
weights. Thus, these variables tend to be selected more often, and the overall quality of solu-
tions increases as the simulation progresses.
Fig 1. Dependence of the length of the ant’s path L (log scale) on the value of R2. As can be seen from this plot, L increases 10-fold as R2
decreases by 0.2 units up to a R2 value of ~0.2, and at a much greater rate for R2 values lower than 0.2.
https://doi.org/10.1371/journal.pone.0245874.g001
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In this work, we used 3,000 ants, and set the initial weights wk(0) to 0.01 and the weight
increment Δw to 0.1. Because of its stochastic nature, this process was repeated 10 times to
minimize the likelihood of accidental convergence to a poor local minimum. The features
identified by each run were used in a subsequent step to construct an ensemble of 10 neural
networks, and each ensemble was cross-validated 10 times (see below).
Neural networks
For each candidate set of K features, a model was derived using three-layer, fully connected
feed-forward artificial neural networks comprised of K inputs, one output, and one hidden
layer, and trained using the standard error back-propagation algorithm [35]. The logistic
transfer function f(x) = 1/(1 + e−x) was used for both hidden and output layers. Each network
was trained for 100 epochs, using a linearly decreasing learning rate from 1.0 to 0.01 and a
momentum of 0.8. During each epoch, the training patterns were presented to the network in
a randomized order.
Neural networks were chosen because of their ability to capture complex nonlinear rela-
tionships. However, neural networks are inherently unstable in that small changes in the train-
ing set and/or training parameters can lead to large changes in their generalization
performance. A proven way to improve the accuracy of unstable predictors is to create multi-
ple instances of them and aggregate their predictions [35]. So-called ensemble techniques,
such as bagging [36], boosting [37], and stacking [38, 39], combine multiple models to achieve
better predictive performance than could be obtained from any of the constituent models.
Obviously, combining the output of multiple predictors is useful only if there is disagreement
between them. Model diversity can be introduced by combining different learning algorithms,
varying the input features, randomizing the training procedure, adding noise to the response
value, or manipulating the training set.
In the present work, each subset of features identified by the artificial ant algorithm was
used to construct 10 independent neural network models using exactly the same network
topology and training parameters but a different random seed number (and thus different ini-
tial synaptic parameters and presentation sequence of the training samples). The predictions
of these 10 models were averaged to produce the aggregate prediction of the ensemble, as illus-
trated in Fig 2. We have found that this approach often outperforms alternative ensemble
methods [40]. We employed this approach for every single run of the feature selection
algorithm.
Cross-validation
Following common practice, the quality of the models was assessed using 10-fold (leave-10%-
out) cross-validation, and quantified using the cross-validated correlation coefficient, R2CV,
which measures the correlation between the actual and the predicted clinical scores. R2CV was
obtained using the jackknife approach, i.e., by dividing the training data into 10 disjoint sub-
sets each containing 10% of the patterns, systematically removing each subset from the train-
ing set, building a model with the remaining patterns, and predicting the clinical scores of the
removed patterns using the optimized network parameters. Once all 10 subsets were processed
in this manner, the resulting predictions were compared to the original clinical scores to deter-
mine their degree of agreement (R2CV). Since cross-validation is itself susceptible to the partic-
ular partitioning of the data samples, each model was cross-validated independently 10 times
using a different random shuffling of the training patterns in order to establish a better esti-
mate of its generalization ability. The same cross-validation procedure was used for both indi-
vidual networks and network ensembles.
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Computational details
Feature selection, neural network modeling and cross-validation were implemented in the C+
+ and C# programming languages and are part of the DirectedDiversity1 [41] and Third
Dimension Explorer [42] software suites. Linear models were built in the R statistical program-
ming environment [43].
Ethics statement
The specific study from which the data has been collected has been expressly approved by the
MIT Committee on the Use of Humans as Experimental Subjects (COUHES), the Burke Reha-
bilitation Hospital IRB, and the NHS National Patient Safety Agency / Gardiner Institute
Western Infirmary of Glasgow University IRB. All participants provided written consent to
participate in this study, and copies of their signed consent forms have been archived. This
consent procedure was approved by all the aforementioned ethics committees/IRBs.
Results and discussion
Descriptive statistics and normalization
Our trial had two primary goals: 1) test whether the RMK metrics can predict the clinical scales
with sufficient accuracy to serve as their surrogates for measuring impairment and recovery in
a non-variable and objective manner, and 2) test whether it is possible to design a more sensi-
tive RMK-based endpoint to measure effect size and thus reduce the sample size of future clini-
cal trials. Endpoint sensitivity was assessed using the standardized paired effect size, defined as
the mean divided by the standard deviation of the day 7 to day 90 changes, aggregated over all
patients.
To enable these analyses, we identified two complementary patient populations: 1) those
with complete data (i.e., no missing values) for days 7 and 90 for all 35 RMK variables and all
four clinical scales (87 patients, 67 from Burke and 20 from Glasgow, hereafter referred to as
Fig 2. Schematic illustration of the ensemble neural network models used to predict the clinical scales from the
RMK variables. Each subset of features identified by the artificial ant algorithm was used to construct 10 independent
neural network models using exactly the same network topology and training parameters but a different random seed
number (and thus different initial synaptic parameters and presentation sequence of the training samples). The
predictions of these 10 models were averaged to produce the aggregate prediction of the ensemble.
https://doi.org/10.1371/journal.pone.0245874.g002
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completers); and 2) those who did not meet these criteria (121 patients, 79 from Burke and 42
from Glasgow, referred to as non-completers). Descriptive statistics of the two subpopulations
are provided in Table 2. All four clinical scales show a statistically significant difference in the
distribution of the completer and non-completer populations when aggregated over the entire
course of the trial, with the former showing a greater degree of impairment. By contrast, no
statistically significant difference was observed in the NIH scores upon admission or the FM,
MP and NIH scores at baseline (day 7), though the completers appear slightly more impaired
on average. In general, different variables showed different directional movement and rates of
progression over time, with substantial variability from patient to patient.
We were well aware that in a relatively large group of patients 7 days post stroke the FM
might include an occasional patient who showed a ceiling effect for the measurement [20],
especially as the accession conditions did not include a damage severity assessment or a mini-
mum motor impairment score. The fact that 5 out of 208 patients had an FM score of 66 by
day 7 strengthens the point of this study because the goal was to establish a biomarker that
would cover the full spectrum of stroke patients and we were concerned that a study con-
ducted exclusively in the US would be limited to patients with very severe to moderate stroke.
The US hospital used in this study is an independent rehabilitation facility admitting referrals
from acute hospitals with severe to moderate strokes, whereas the UK hospital is an integrated
facility that cares for patients with both acute and chronic stroke. This is reflected in our results
which show that the highest FM patient score admitted in our study in the US was 46 (max 66)
at day 7, while the mean score of patients admitted to the UK facility was 39.
Correlation analysis
An intuitive way to visualize the correlation structure of the RMK data set is to embed the 35
robotic and four clinical variables into a two-dimensional nonlinear map in a way that pre-
serves as much as possible the pairwise correlations between them. The map shown in Fig 3
contains a point for each RMK and clinical metric and was constructed using stochastic prox-
imity embedding (SPE) [44–46] so that the distances of the points on the map match as closely
as possible the correlation distances of the corresponding features, defined as dij = 1 –abs(Rij),
where Rij is the Pearson correlation coefficient between the i-th and j-th features computed
over all patients and time points. Thus, correlated (and anti-correlated) features appear close
to each other on the map, whereas uncorrelated ones appear further apart (note that the actual
distance between two points is a function of not only the correlation between these two fea-
tures alone, but to all the other features as well–the map reproduces all pairwise distances in a
least-squares sense).
Several observations emerge from this map. First, the four clinical scales (highlighted in
red) show a substantial degree of correlation to each other as compared to the majority of the
RMK variables, with FM and MP exhibiting very similar correlation profiles and being highly
correlated themselves (R = 0.933). This is consistent with the findings of Bosecker et al [14]. on
chronic stroke patients (111 patients, R = 0.785) as well as previous studies of subacute stroke
by Ferraro et al. [47] (12 patients, R = 0.981) and Krebs et al. [8] (56 patients, R = 0.981), and
shows the tight coupling of strength (MP) and isolated joint movement (FM).
Second, the RMK variables on the affected side (in blue) exhibit substantially greater corre-
lation to the clinical scales compared to the non-affected side (in green). Among all the RMK
metrics, Rnd Dyn Mean Dist, Aim, Deviation, Smooth J1, Plbck Mean, and Ellipse exhibit the
highest correlation to the clinical scores both on the affected and the unaffected sides, but sub-
stantially more so on the affected side. Finally, the map reveals distinct clusters of correlated
variables which are preserved on both the affected and unaffected sides (outlined by green and
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Table 2. Descriptive statistics.
Completers Non-Completers Total
Count Min Max Mean StdDev Median Count Min Max Mean StdDev Median Count p-value
Demographics Age 87 29 96 70.552 13.860 73 121 22 97 73.521 13.522 76 208 1.3E-01
Sex | Male 43 63 106
Sex | Female 44 58 102
Ethnicity | Caucasian 66 98 164
Ethnicity | Hispanic 6 8 14
Ethnicity | Asian 1 2 3
Ethnicity | African American 14 13 27
Handedness | Right 58 80 138
Handedness | Left 8 10 18
Handedness | Left / Right Writing 0 1 1
Handedness | Unknown 21 30 51
Affected Side | Right Body 32 40 72
Affected Side | Left Body 35 51 86
Affected Side | Unknown 20 30 50
Site | Burke 67 79 146
Site | Glasgow 20 42 62
Clinical Scales NIH Admission 51 1 27 10.860 6.470 11 77 1 27 10.390 5.910 9 128 6.8E-01
FM Day 7 87 4 66 40.250 21.650 45 91 4 66 38.490 21.930 41 178 5.9E-01
MP Day 7 87 2 70 45.490 20.140 50 73 0 70 39.290 21.710 43 160 6.5E-02
NIH Day 7 87 0 24 5.750 4.270 5 93 0 21 6.490 4.860 6 180 2.8E-01
FM 403 4 66 48.790 20.030 58 391 0 66 44.430 22.600 54 794 4.2E-03
MP 402 2 70 52.270 17.830 56 314 0 70 45.360 21.500 53 716 5.2E-06
NIH 404 0 24 3.540 3.720 2 408 0 21 4.590 4.500 3 812 3.1E-04
MR 165 0 5 2.350 1.280 2 129 0 5 2.820 1.250 3 294 1.7E-03
RMK Metrics Aim Aff 404 0.003 1 0.176 0.122 0.144 377 0 0.79 0.210 0.144 0.172 781 4.1E-04
Aim NonAff 404 0 0.931 0.245 0.138 0.215 380 0.031 1 0.272 0.151 0.245 784 9.3E-03
Deviation Aff 402 0.005 0.848 0.093 0.106 0.06 381 0 1 0.128 0.164 0.072 783 4.5E-04
Deviation NonAff 404 0 1 0.092 0.101 0.067 377 0.001 0.873 0.122 0.141 0.078 781 7.2E-04
Dist Subm Aff 404 0.01 1 0.364 0.126 0.358 368 0 0.754 0.374 0.135 0.369 772 2.9E-01
Dist Subm NonAff 404 0.036 1 0.344 0.129 0.334 381 0 0.749 0.376 0.137 0.369 785 8.0E-04
Dur Subm Aff 404 0.173 1 0.493 0.134 0.491 369 0 0.831 0.479 0.140 0.486 773 1.6E-01
Dur Subm NonAff 404 0.262 1 0.600 0.134 0.589 381 0 0.977 0.612 0.130 0.613 785 2.0E-01
Duration Aff 404 0.044 1 0.234 0.134 0.201 380 0 0.894 0.266 0.162 0.226 784 2.8E-03
Duration NonAff 404 0.035 0.855 0.207 0.126 0.175 381 0 1 0.257 0.149 0.227 785 5.2E-07
Ellipse Aff 403 0.999 1 1.000 0.000 1 379 0 1 0.992 0.089 1 782 8.1E-02
Ellipse NonAff 404 0.002 1 0.755 0.183 0.818 380 0 0.988 0.734 0.188 0.793 784 1.1E-01
Max Subm Aff 404 0.031 0.77 0.339 0.133 0.323 369 0 1 0.319 0.156 0.292 773 5.7E-02
Max Subm NonAff 404 0.018 0.775 0.321 0.152 0.303 381 0 1 0.283 0.160 0.258 785 6.9E-04
Mean Speed Aff 404 0.007 0.689 0.299 0.111 0.29 380 0 1 0.281 0.138 0.267 784 4.5E-02
Mean Speed NonAff 404 0.008 1 0.318 0.136 0.313 377 0 0.814 0.279 0.146 0.269 781 1.3E-04
Mean Z Aff 404 0.816 1 0.849 0.029 0.842 328 0 0.914 0.829 0.094 0.835 732 2.2E-04
Numb Subm Aff 404 0 0.858 0.181 0.128 0.156 369 0.008 1 0.218 0.156 0.185 773 3.6E-04
Numb Subm NonAff 404 0 1 0.161 0.133 0.124 381 0.006 0.922 0.213 0.152 0.179 785 4.5E-07
Overlap Subm Aff 404 0.056 1 0.453 0.128 0.443 367 0 0.761 0.432 0.125 0.434 771 2.2E-02
Overlap Subm NonAff 404 0.16 1 0.491 0.149 0.482 379 0 0.93 0.482 0.130 0.48 783 3.7E-01
Peak Speed Aff 404 0.05 0.833 0.397 0.133 0.377 380 0 1 0.379 0.152 0.36 784 7.9E-02
Peak Speed NonAff 404 0.057 0.801 0.359 0.150 0.343 377 0 1 0.318 0.155 0.306 781 1.9E-04
Plbck Mean Aff 404 0 0.961 0.170 0.171 0.098 377 0.003 1 0.212 0.188 0.147 781 1.2E-03
Plbck Mean NonAff 403 0.003 0.823 0.139 0.170 0.063 383 0 1 0.164 0.167 0.089 786 3.8E-02
Rnd Dyn Mean Dist Aff 404 0.017 0.975 0.728 0.258 0.866 380 0 1 0.670 0.300 0.86 784 3.9E-03
Rnd Dyn Mean Dist NonAff 404 0 0.982 0.770 0.120 0.797 381 0.106 1 0.752 0.148 0.796 785 6.3E-02
Sigma Subm Aff 404 0.165 1 0.456 0.124 0.46 369 0 0.801 0.436 0.124 0.447 773 2.5E-02
Sigma Subm NonAff 404 0.212 1 0.553 0.132 0.546 381 0 0.905 0.550 0.117 0.55 785 7.4E-01
Smooth J1 Aff 404 0.029 0.942 0.170 0.101 0.143 375 0 1 0.192 0.128 0.154 779 8.2E-03
Smooth J1 NonAff 404 0 0.466 0.123 0.059 0.114 381 0.005 1 0.128 0.091 0.109 785 3.6E-01
Smooth J2 Aff 404 0 0.588 0.114 0.075 0.096 378 0.003 1 0.121 0.118 0.086 782 3.3E-01
Smooth J2 NonAff 404 0 0.39 0.084 0.055 0.074 380 0 1 0.076 0.077 0.059 784 9.6E-02
Smooth M/P Aff 404 0 0.967 0.579 0.129 0.601 380 0.111 1 0.550 0.150 0.562 784 3.9E-03
Smooth M/P NonAff 404 0 1 0.500 0.135 0.524 377 0.017 0.848 0.470 0.147 0.484 781 3.1E-03
RMK metrics are normalized across all patients and assessment points. Statistics for clinical scales and RMK metrics are based on total number of patient assessments.
p-values that indicate a statistically significant difference between completers and non-completers are highlighted in red.
https://doi.org/10.1371/journal.pone.0245874.t002
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blue ellipses, respectively). These clusters include: 1) Overlap Subm, Sigma Subm and Dur
Subm; 2) Rnd Dyn Mean, Aim, and Deviation; 3) Peak Speed,Mean Speed,Max Subm, Dist
Subm, and Smooth J2; and 4) Numb Subm,Duration, and Smooth M/P. While we only mea-
sured FM and MP on the ipsilesional side, these results seem to suggest that motor effects cas-
cade to the contralesional side as well.
Given the degree of redundancy among the RMK metrics, we used principal component
analysis (PCA) to estimate the number of underlying independent variables and thus the
intrinsic dimensionality of the RMK data. The first 3 PCs account for 59% of the total variance
in the data, while 10, 14 and 22 PCs are required to reach the 90%, 95% and 99% levels, respec-
tively. (Note that the limited size of our data set precluded the use of more elaborate geodesic
approaches for detecting nonlinear manifolds, such as isometric SPE [45], isomap [48], or
locally linear embedding [49]. In general, PCA tends to overestimate the true dimensionality
of a data sample.).
Fig 3. SPE map of the correlation distances of the clinical and RMK parameters for the completers cohort. The
map was derived by computing the pairwise Pearson correlation coefficients (R) for all pairs of features, converting
them to correlation distances (1-abs(R)), and embedding the resulting matrix into 2 dimensions in such a way that the
distances of the points on the map approximate as closely as possible the correlation distances of the respective
features. The clinical parameters are highlighted in red, the RMK parameters on the affected side in blue, and the RMK
parameters on the unaffected side in green. The map also shows distinct clusters of correlated variables which are
preserved on both the affected and unaffected sides (outlined by green and blue ellipses, respectively).
https://doi.org/10.1371/journal.pone.0245874.g003
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Prediction of clinical scales
Models were derived independently for each clinical scale, using the completer population for
training and cross-validation, and the non-completer population for external validation. Since
the number of optimal features is not known a priori and the generalization error is largely
determined by the ratio of training samples to adjustable parameters in the model, feature
selection was run with varying numbers of input features k (2, 4, 6, 8, 10, 12, 14) and hidden
units h (1, 2, 3). The artificial ant algorithm was run five times for each combination of k and
h, and the features identified in each run were, in turn, used to derive ensemble models com-
prising 10 individual predictors. Finally, each resulting ensemble (along with its constituent
individual networks) was cross-validated 10 times using 10-fold cross-validation. This entire
process was repeated separately for each of the four clinical scales. Thus, our modeling effort
involved the generation and training of 4 × 7 × 3 × 5 × 10 × (10+1) × 10 = 462,000 individual
neural networks (where 10+1 accounts for the 1 training and 10 cross-validation runs for each
network).
The models with two hidden units were slightly better than those with one and virtually
identical to those with three, so the remaining discussion is based on the models with two hid-
den units. Similarly, other training parameters, such as momentum, initial synaptic weights
and number of training epochs, had minimal impact on the generalization error and were set
to the values outlined in the Methods section. Although, as we discuss later, there were distinct
differences among clinical scales, all models showed good predictive power, with the cross-val-
idated R2s ranging from 0.48 to 0.73 for individual networks, and 0.50 to 0.75 for network
ensembles. Model aggregation improved the results in all cases, both in terms of predictive
ability (the R2CVs of the ensembles were on average 0.02 units greater than those of the corre-
sponding individual predictors) as well as robustness (standard deviation was reduced by a fac-
tor of two to three). The training R2’s were on average 0.05 units higher than the cross-
validated R2’s.
The results are summarized in Fig 4. The solid lines represent the average ensemble cross-
validated R2 of the best model for each clinical scale as a function of the number of input fea-
tures, aggregated over all cross-validation runs. This plot reveals several trends. First, model
performance exhibits an asymptotic behavior with respect to the number of features, reaching
the point of diminishing return at approximately 8 features for all four clinical scales. Second,
the models for the FM and MP display comparable predictive power, which is not surprising
given the strong correlation between them. Further, performance was not uniform across the
four clinical scales. The FM and MP models are more predictive than those for NIH and MR,
with the latter showing substantial deficits both in terms of predictiveness (mean) and robust-
ness (standard deviation). It should be noted, however, that the MR models were derived from
substantially fewer training samples, as we only had data available for days 30 and 90. At the
optimal 6–10 feature range, the R2CV for NIH and MR are 0.1–0.13 units lower than that of
FM and MP, which suggests that the NIH and MR scales encode additional elements of patient
function that are not captured by the robotic assay or are inherently more noisy.
More importantly, the ensemble models retain much of their predictive power on the non-
completer population, as illustrated by the dotted lines in Fig 4. These are patients who were
not ‘seen’ by the model during training, and represent an excellent external validation set. The
R2 of the best 8-feature models for FM, MP and MR are 0.60, 0.59 and 0.58, respectively, while
that of NIH is 0.42. Although these values are lower than those obtained from cross-validation,
the models are still highly predictive. Again, for most of the clinical scales, performance pla-
teaus at around 8 features with the exception of NIH where there is a spike in predictive power
for 6 features.
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Our models are markedly better than those derived by Bosecker et al. on patients with
chronic stroke [14]. To reduce the number of dimensions, in that work we used PCA on all
kinematic and kinetic metrics as a filter prior to regression, and used multi-linear regression
to derive the actual models. The observed differences in predictive power could be due to a
number of factors, including the type and number of patients employed in the two studies, the
use of neural networks as opposed to multi-linear regression (MLR), and/or the use of a more
elaborate feature selection algorithm. To directly compare the two methods, we used the same
PCA technique to select the 8 most important features, and derived new multi-linear regres-
sion models using our new training set (the same completer population). The 8 features identi-
fied by PCA were all on the affected side and included Aim, Deviation,Mean Speed, Peak
Speed, Smooth J1, Ellipse, Rnd Dyn Mean Dist, andMean Z. In addition, to further distinguish
the effects of feature selection and linearity, the 8 features that produced the best neural net-
work ensembles by cross-validated R2 for each clinical scale were used to construct equivalent
linear models by MLR. All of these models were cross-validated using the same 10-fold cross-
validation procedure described in the Methods session, so that their generalization ability
could be directly compared.
As can be seen in Fig 5, the use of neural networks coupled with the artificial ant algorithm
afford significant benefits, improving the R2 by 0.09 for FM, 0.04 for MP, 0.08 for NIH, and a
dramatic 0.17 for MR. Most of these gains appear to stem from the use of nonlinear modeling;
the difference in the R2 between ANTS-MLR and PCA-MLR for FM, MP and MR is only
~0.01, except for NIH where the features selected by the artificial ants are markedly better even
in a linear context. These differences are only partly explained by the use of ensembles, which
accounts for only a ~0.02 improvement of R2 compared to individual networks. (Note that
MLR is a stable predictor that does not benefit from this particular form of aggregation.).
Fig 4. Cross-validated R2 of the best models derived from the completers (solid lines) and validated with the non-
completers (dashed lines) for each of the four clinical scales, using 2, 4, 6, 8, 10, 12 and 14 robot-derived RMK
features. The figure shows the ability of the robot-derived RMK models to predict the clinical scales with an increasing
number of features. The model performance exhibits an asymptotic behavior with respect to the number of RMK
features, reaching the point of diminishing returns at approximately 8 features for all four clinical scales. Note the small
variance in the prediction of the trained data as shown by the small “whiskers,” which for the most part, are not visible
in the figure.
https://doi.org/10.1371/journal.pone.0245874.g004
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Importance of individual features
One of the goals of our analysis was to gain a more quantitative understanding of what each of
the clinical instruments is trying to measure, how they differ from each other, where they fall
short, and how we can design alternative scales with greater sensitivity and ability to detect
finer differences in motor function.
Given the complex correlation structure of the RMK metrics, the features that are selected
by the feature selection algorithm are not necessarily the only ones that can produce a high
quality model. The SPE map in Fig 3 shows clusters of highly correlated RMK metrics which
could, in theory, be interchangeable in the models. Further, there may be features that can be
replaced by a small group of other features as opposed to a single one and still yield a model of
comparable predictive power.
To assess the importance of each feature in predicting the various clinical scales, we system-
atically removed each feature from our training sample and repeated the feature selection,
aggregation and cross-validation procedure for each derived data set. Given the computation-
ally intensive nature of this exercise and our previous observations regarding the optimal num-
ber of features and hidden units, this process was only tested with models with 8 input and 2
hidden units. The results are summarized in Fig 6.
The left-most data point and the horizontal solid line on the top part of the plot represent
the cross-validated R2 of the best model with all features included, averaged over all 10 cross-
validation runs (standard deviations shown as error bars). Each subsequent point shows the R2
of the corresponding apomodel, i.e., the model derived by omitting the feature shown on the x
axis. The individual markers at the bottom part of the plot indicate a statistically significant
Fig 5. Cross-validated R2 of the best 8-feature models derived using three different approaches for feature
selection and model building: 1) features selected by artificial ants with neural networks, model derived with
neural networks (dark blue); 2) features selected by artificial ants with neural networks, model derived with
multi-linear regression (light blue); and 3) features selected by PCA, model derived with multi-linear regression
(red). Every model was cross-validated using the same 10-fold cross-validation procedure described in the Methods
session.
https://doi.org/10.1371/journal.pone.0245874.g005
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difference between the R2 distributions of the all-feature and the respective apomodels (the
presence of a marker indicates that the difference between the two distributions is statistically
significant, and the absence that it is not).
For FM and MP, the most critical feature is Rnd Dyn Mean Dist Aff, and its omission results
in a 0.04 and 0.07 drop in R2 for FM and MP, respectively. Deviation Aff and Dist Subm Aff
also appear important for both scales, but the effect is small (0.01 on the R2 scale) and could be
an artifact of the small sample size (only 10 cross-validation runs). This confirms that both the
FM and MP scales are motor impairment-based scales and can rely on the ability of a patient
to exert force in a coordinated manner, which can be captured reliably by a robotic device.
A number of features appear significant for NIH, including Rnd Dyn Mean Dist Aff, Plbck
Mean Aff, Peak Speed Aff, Smooth M/P Aff, Deviation Aff and Deviation NonAff. This suggests
that the NIH stroke scale has a more global and coarser nature Finally, for the MR scale, Aim
Aff emerges as the most important feature, followed by Rnd Dyn Mean Dist Aff, Plbck Mean
Aff,Mean Speed NonAff, Dist Subm Aff, and Dist Subm NonAff. The large number of relevant
features suggests that the MR scale is coarser than the three other clinical scales, which is not
surprising given the low correlation between them (Fig 4).
Rnd Dyn Mean Dist Aff is the only feature that is important for all four clinical scales, and
its effect eclipses that of any other RMK variable (except Aim Aff for MR). This finding, along
Fig 6. Importance of individual RMK features in predicting the four clinical scales, obtained by systematically removing each feature from the
training sample and repeating the feature selection, aggregation and cross-validation procedure for each derived data set. Only models with 8
input and 2 hidden units are shown. The left-most data point and the horizontal solid line on the top part of the plot represent the cross-validated
R2 of the best model with all features included, averaged over all 10 cross-validation runs (standard deviations shown as error bars). Each
subsequent point shows the R2 of the corresponding apo model, i.e., the model derived by omitting the feature shown on the x axis (the model still
includes 8 features, just not the one shown on the x axis). The individual markers at the bottom part of the plot indicate whether there is a
statistically significant difference between the R2 distributions of the all-feature and the respective apo models (the presence of a marker indicates
that the difference between the two distributions is statistically significant, and the absence that it is not).
https://doi.org/10.1371/journal.pone.0245874.g006
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with the high generalization ability of all the models, suggests that these clinical instruments
depends heavily on a person’s motor impairment measurement and as such can be easily
replaced with an objective device. It also means that other potentially other relevant aspects of
stroke recovery may be missed by these scales, e.g. depression level. While it is not surprising
that the features that emerge as most critical in deriving nonlinear models are also among
those most correlated to the clinical scales (see Fig 4), it is also clear that the importance of a
feature cannot be deduced solely from correlation or in isolation from other feature combina-
tions. Most features can be replaced by other features or groups of features, and many configu-
rations exist that can yield equally predictive models.
Maximizing effect size with novel composites
At this point, we have demonstrated that a small number of RMK invariants can predict the
clinical scales with sufficient accuracy to serve as a proxy for measuring impairment in an
objective and unbiased manner. As seen in Fig 7, minimizing the inter-rater variability leads to
a significant increase in the effect size vs. the historical average. However, if we simply repli-
cated a scale in which there are significant floor or ceiling effects we would not be taking full
advantage of the InMotion apparatus. For instance, in this trial, there are individuals with a
FM score of 66, which is well within the normal range. These individuals had a stroke that was
mild enough, such that it would be difficult to assess improvement over time with the tradi-
tional scales.
Thus, our second goal was to determine whether we could improve the sensitivity of the
clinical endpoints by means of a novel RMK-based composite that could be used to measure
effect size in future clinical trials. We have already seen that motor impairment play a domi-
nant role in all clinical scales, but the relative weight of each of these components differs from
one scale to another. We hypothesized that by rebalancing these weights we could detect finer
improvements in a patient’s condition over a short period of time. Therefore we sought to
Fig 7. Optimization of effect size for robot-derived RMK metrics. The horizontal lines show the day 7 to day 90
effect size for comparable patients of the historical VISTA data for the NIH, as well as the effect sizes for the NIH, FM
and MP assessment scales for our completers cohort. The figure also shows the performance of the robot-derived RMK
composites optimized for effect size for the trained (solid lines) and cross-validated sets (dashed lines). Note the
increase of over 20% in cross-validated effect size for the RMK composites over the clinical scales with 4-features for
this study (and over 70% over the historical data).
https://doi.org/10.1371/journal.pone.0245874.g007
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create a composite scale made exclusively of RMK metrics and determine whether it could
improve our ability to distinguish patient improvement from day 7 to day 90. While no treat-
ment was administered, our assumption was that there would be some natural recovery during
the acute and sub-acute stroke phase.
Effect size was assessed using Cohen’s d for paired observations, defined as the mean
divided by the standard deviation of the day 7 to day 90 changes over the entire completer pop-




wðiÞ � rmk2ði; jÞ ð5Þ
where RMK(i, j) represents the ith feature of the jth patient, and w(i) represents the weight of
that feature. Eq 5 implicitly assumes that w(i) will be non-zero for only a specific number of
features. To ensure clinical relevance, we set the maximum number of features with non-zero
coefficients to 8, and limited the choice to only the features found by the neural networks (we
examined separately the three groups of 8 features found in the best models of the three clinical
scales). Thus, given a particular set of 8 features, the challenge was to identify the subset of fea-
tures and corresponding weights that maximized Eq 5. (Unlike the fitting of clinical scales,
maximizing the effect size using a nonlinear model would make the problem ill-posed [50].
With prediction, there is a cap on how well a model can perform: a perfect prediction. There is
no such intrinsic upper bound on the standard effect size, which can, in theory, be driven to
infinity with the use of higher order terms.).
We solved this problem using a greedy forward selection algorithm. Briefly, the algorithm
constructed composites by adding one feature at a time until all 8 preselected RMK endpoints
were included. The process started by identifying the feature that yielded the maximum effect
size and assigning to it a weight of 1. Each remaining feature was then examined in turn, and
the one that yielded the largest effect size in combination with the previously selected feature
was added to the composite. The algorithm continued in this fashion progressively building
larger composites until all 8 features were included. At each step, each candidate feature was
evaluated using 18 discrete weights ranging from -1 to +1 in increments of 0.1, while keeping
the coefficients of the already selected features at their previously optimized values. Once the
feature was selected, the weights of all the features in the current composite were refined in an
iterative fashion until the effect size no longer improved. (An alternative backward elimination
algorithm was also employed but produced inferior results. That method started by including
every preselected RMK endpoint in the composite and optimizing their coefficients using the
Newton-Raphson gradient minimization procedure. The feature with the smallest weight was
then identified and removed from the composite, the weights of the remaining features were
re-optimized, and the process continued in the same fashion until a single feature remained.).
As with the prediction of clinical scales, cross-validation is necessary to ensure that the
resulting composites are meaningful beyond the training set. Thus, for each of the three groups
of 8 features used in the most predictive models of MP, FM, and NIH, respectively, the forward
selection algorithm was repeated 100 times, each time using a different, randomly chosen 80%
of the patients to build up the composites and reserving the remaining 20% for testing.
The results are summarized in Fig 7, which plots the average effect size for the training and
validation sets as a function of the number of features included in the composite (each point
represents the average of 100 cross-validation runs). The blue, green and red solid horizontal
lines represent the effect sizes of the FM, MP and NIH clinical scales, and serve as reference
points for evaluating the sensitivity of the RMK composites. Overall, the NIH stroke scale is
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the most effective in assessing change from baseline (effect size of 1.07), followed by Motor
Power (1.03) and Fugl-Meyer (0.97).
For the RMK measurements, no single feature performs as well as the clinical scales, which
is not surprising given that the latter encapsulate multiple RMK measures, as demonstrated
earlier. The effect size increases sharply as additional features are added, exceeds the clinical
scales by as much as 30% for the training and 20% for the validation set with only four features,
and then plateaus offering little additional improvement. As expected, the effect size is signifi-
cantly lower for the validation than for the training set and is also more variable.
In order to test the sensitivity of these robot-assisted surrogate markers against historical
data, we selected a subset of 2,937 patients from the Virtual International Stroke Trials Archive
(VISTA) [51, 52] with a comparable degree of stroke severity as measured by the NIH at day 7.
These historical patients were chosen at random so as to match the frequency distribution of
NIH scores at day 7 of our current study population, which ranged from 0 to 24. More specifi-
cally, for each one of our current study patients, nearly 14 subjects were selected at random
from the VISTA registry with the same NIH score measured at day 7. This process yielded a
cohort that had the same proportion of patients within each NIH point. This group of 2,937
patients had a day 7 mean NIH score of 5.7 ± 4.1 that improved by 2.1 ± 3.1 points at day 90,
giving a standardized effect size of 0.67 for the changes from day 7 to day 90 (illustrated by the
red dashed line in Fig 7).
As seen in Fig 7, optimized RMK composites with as few as four features increased the
effect size over the historical VISTA level by as much as 107% for the training and 83% for the
validation set. This result is highly significant and cannot be attributed to motor learning, as
we demonstrated the stability of the RMK measurements on both persons with chronic stroke
and age-matched controls. An increase of 83% in effect size compared to the validated set
would result in a 70% reduction in the number of patients required to achieve the typical 80%
statistical power in a clinical trial. It is worth pointing out that the increase in effect size seen in
this natural history trial is not the effect size that one would expect to see in a conventional
clinical trial, which is designed to compare the effect of therapy over placebo. It must also be
noted that clinical scales represent the best case scenario of relying on a handful of highly
trained clinical raters, whereas the composite ought to be highly consistent across multiple
sites due to the lack of subjectivity in the assessment.
While the underlying RMK metrics were identical to those used to reconstruct the NIH
stroke scale, our modeling effort reweighted each of the individual components, enhancing
our ability to detect smaller improvements in our patient population. One surprising aspect of
our modeling was that sub-movements do not seem to play a significant role in the new com-
posites. We speculate that sub-movements features might be less important when dealing with
coarse aspects of motor abilities and the clinical scales generally employed to measure them.
As illustrated in Fig 8, the composites obtained with the greedy algorithm are correlated
with all three clinical scales, with the R2s ranging from 0.34 to 0.45. On the basis of these
results, we would recommend the composite derived from the 8 features identified by the best
NIH neural network model, since it offers the largest effect size for both the training and the
validation set, and shows the most consistent correlation with all three clinical scales (0.37,
0.38 and 0.39 for MP, FM, and NIH, respectively).
These results strongly suggest that robotic measurement of motor function may be a viable
and improved method for capturing clinical outcomes over traditional clinician-rated mea-
sures, and can greatly reduce the sample size required for future clinical trials, thus improving
study cost and efficiency. The computational methodology described in this work is not lim-
ited only to stroke, but can be applied also to a broad range of problems in medical diagnostics
and remote monitoring. While the general clinical findings were described in our earlier
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publication, the present paper offers greater insights into the relative significance of strength
and coordination, and the importance of each robotic feature in capturing different aspects of
stroke recovery.
Future work
In this work, we have established that we are able to accurately replicate the traditional stroke
evaluation scales from robotic measurements with a high degree of accuracy, and that a
straightforward re-weighting of the features needed to reconstruct the traditional scales can
yield a novel composite that is significantly more sensitive than the traditional scales for mea-
suring improvement over time. This has allowed us to establish that, for a fixed time interval,
we can greatly reduce the number of patients needed to power a clinical trial.
Our current work has established a composite that works well over the 90 day assessment
window. However, given sufficient amounts of data, it would be possible to tune the composite
for a patient’s individual level of impairment. The reason for this is that stroke recovery may
not progress in a consistent fashion, and initial recovery to stoke may be more sensitive on
some metrics vs others. Being able to identify and pre-specify sensitive composites over a spe-
cific range of severities would allow us to better tune it towards a patient population and fur-
ther shrink the number of patients needed for a given clinical trial. Given the design of this
trial and the confounding issue of patient improvement over time, it was not possible for us to
assess the inherent variability in human performance. Answering this question could provide
valuable insights into determining how long a trial needs to run for patients to stand a good
chance of showing functional improvement to their physical well-being.
Conclusions
The results described above are extremely promising but must be interpreted with appropriate
caution. The population enrolled in our study was highly selected, with a day 7 mean NIH
score of 5.7 ± 4.1. Clearly, any gains in statistical power will need to be balanced against lower
enrollment rates imposed by the selection criteria and against potential failure to complete fol-
low-up or to comply with the RMK measurements. Additionally, while the RMK lends itself to
Fig 8. Correlation (expressed as R2) of the FM, MP and NIH original scales with the corresponding optimized
8-feature composites obtained with the greedy algorithm.
https://doi.org/10.1371/journal.pone.0245874.g008
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repeated assessments to produce averaged measurements, the same might be true if we employ
ordinal analysis, central adjudication by multiple raters, and global testing procedures that
combine complementary scales across clinical domains and across time (albeit at much greater
expense). Finally, there was substantially greater improvement in the NIH scores achieved by
our current pool of completers compared to historical patients with comparable variability
(VISTA). The pool of 2,937 patients selected in the VISTA registry to match the distribution of
our pool of 208 patients at day 7 had an improvement of 2.1 ± 3.1 by day 90, while our comple-
ters had an improvement of 3.7 ± 3.3. This difference must be interpreted with appropriate
caution given that the historical patient data was obtained at a different time and in different
institutions, a factor that inevitably introduces some bias.
Despite the generally limited penetration of robotic technologies in the post-stroke neuror-
ehabilitation arena (only 200 InMotion Arm robots have been produced so far), taken
together, our results suggest that robotic measurements may enable early decision making in
clinical testing, reduce required sample sizes, and offer a more reliable method to track longi-
tudinal change in patients affected by stroke than using current clinical instruments. More
importantly, this study marks a novel beginning for technology-enabled measurement of out-
comes, and offers a proof-of-principle for other robotic and wearable devices potentially
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